N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial

Journal of Clinical Psychopharmacology

Volumn 32, Issue 6, 2012, Pages 797-803

  Afshar, Hamid ^a   Roohafza, Hamidreza ^b   Mohammad Beigi, Hamid ^c   Haghighi, Mohammad ^d   Jahangard, Leila ^d   Shokouh, Pedram ^b   Sadeghi, Masoumeh ^e   Hafezian, Hasan ^d  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

acetylcysteine; Clinical Global Impression scale; obsessive compulsive disorder; randomized controlled trials; Yale Brown obsessive compulsive scale

Indexed keywords

ACETYLCYSTEINE; FLUVOXAMINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MULTICENTER STUDY; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ACETYLCYSTEINE; ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870252343     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318272677d     Document Type: Article

References (45)

1. Emsley RA. Partial response to antipsychotic treatment: The patient with enduring symptoms. J Clin Psychiatry. 1999;60(suppl 23):10-13.
2. Greenberg BD, Price LH, Rauch SL, et al. Neurosurgery for intractable obsessive-compulsive disorder and depression: Critical issues. Neurosurg Clin N Am. 2003;14(2):199-212. (Pubitemid 36514460)
3. Stein DJ. Obsessive-compulsive disorder. Lancet. 2002;360(9330):397-405.
4. Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995;166(4):424-443.
5. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):400-412.
6. Ferrao YA, Diniz JB, Lopes AC, et al. Resistance and refractoriness in obsessive-compulsive disorder. Rev Bras Psiquiatr. 2007;29(suppl 2):S66-S76.
7. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx. 2006;3(1):69-81. (Pubitemid 43276634)
8. Hollander E. Obsessive-compulsive disorder-related disorders: The role of selective serotonergic reuptake inhibitors. Int Clin Psychopharmacol. 1996;11(suppl 5):75-87. (Pubitemid 27049282)
9. Figueroa Y, Rosenberg DR, Birmaher B, et al. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol. 1998;8(1):61-67. (Pubitemid 28270779)
10. March JS, Frances A, Kahn DA, et al. Treatment of obsessive-compulsive disorder. The expert consensus panel for obsessive-compulsive disorder. J Clin Psychiatry. 1997;58 (suppl 4):2-72.
11. Van Noppen BL, Pato MT, Marsland R, et al. A time-limited behavioral group for treatment of obsessive-compulsive disorder. J Psychother Pract Res. 1998;7(4):272-280. (Pubitemid 28409159)
12. Decloedt EH, Stein DJ. Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2010;6:233-242.
13. Insel TR, Mueller EA, Alterman I, et al. Obsessive-compulsive disorder and serotonin: Is there a connection? Biol Psychiatry. 1985;20(11):1174-1188.
14. Bhattacharyya S, Chakraborty K. Glutamatergic dysfunctionVnewer targets for anti-obsessional drugs. Recent Pat CNS Drug Discov. 2007;2(1):47-55. (Pubitemid 46729090)
15. Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23(3):563-586. (Pubitemid 30666507)
16. Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30(9):1735-1740. (Pubitemid 43086030)
17. McGrath MJ, Campbell KM, Parks CR, et al. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res. 2000;877(1):23-30.
18. Nordstrom EJ, Burton FH. A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry. 2002;7(6):617-625.
19. Arnold PD, Sicard T, Burroughs E, et al. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry. 2006;63(7):769-776.
20. Pittenger C, Bloch M, Wegner R, et al. Glutamatergic dysfunction in obsessive-compulsive disorder and the potential clinical utility of glutamate-modulating agents. Primary Psychiatry. 2006;13(10):65-77. (Pubitemid 44571910)
21. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Biol Psychiatry. 2005;58(5):424-428. (Pubitemid 41219711)
22. Poyurovsky M, Weizman R, Weizman A, et al. Memantine for treatment-resistant OCD. Am J Psychiatry. 2005;162(11):2191-2192.
23. Stewart SE, Jenike EA, Hezel DM, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30(1):34-39.
24. Pendyala L, Creaven PJ. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiol Biomarkers Prev. 1995;4(3):245-251.
25. Scalley RD, Conner CS. Acetaminophen poisoning: A case report of the use of acetylcysteine. Am J Hosp Pharm. 1978;35(8):964-967. (Pubitemid 8397784)
26. Moran MM, McFarland K, Melendez RI, et al. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci. 2005;25(27):6389-6393. (Pubitemid 40962534)
27. Mathew SJ, Price RB, Charney DS. Recent advances in the neurobiology of anxiety disorders: Implications for novel therapeutics. Am J Med Genet C Semin Med Genet. 2008;148C(2):89-98. (Pubitemid 351705126)
28. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: A pilot study. Biol Psychiatry. 2007;62(6):652-657. (Pubitemid 47314380)
29. Odlaug BL, Grant JE. N-acetyl cysteine in the treatment of grooming disorders. J Clin Psychopharmacol. 2007;27(2):227-229. (Pubitemid 46594953)
30. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: A double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66(7):756-763.
31. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2006;184(2):254-256. (Pubitemid 43084809)
32. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011. (Pubitemid 19278229)
33. Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology, Revised DHEW Publication (ADM). Rockville, MD: National Institute for Mental Health; 1976:218-222.
34. Kumar TC, Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry. 2000;34(3):527-528. (Pubitemid 30389427)
35. Ozkara C, Ozmen M, Erdogan A, et al. Topiramate related obsessive-compulsive disorder. Eur Psychiatry. 2005;20(1):78-79. (Pubitemid 40092398)
36. Ng F, Berk M, Dean O, et al. Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11(6):851-876.
37. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36(2):78-86.
38. Aruoma OI, Halliwell B, Hoey BM, et al. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6(6):593-597. (Pubitemid 19147809)
39. Selek S, Herken H, Bulut M, et al. Oxidative imbalance in obsessive compulsive disorder patients: A total evaluation of oxidant-antioxidant status. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):487-491. (Pubitemid 351187832)
40. Ersan S, Bakir S, Erdal EE, et al. Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1039-1042. (Pubitemid 43928217)
41. Han D, Sen CK, Roy S, et al. Protection against glutamate-induced cytotoxicity in C6 glial cells by thiol antioxidants. Am J Physiol. 1997;273(5 Pt 2):R1771-R1778. (Pubitemid 27518131)
42. Malek-Ahmadi P. Role of cytokines in psychopathology: Therapeutic implications. Drug News Perspect. 1998;11(5):271-276. (Pubitemid 28355864)
43. Khan M, Sekhon B, Jatana M, et al. Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J Neurosci Res. 2004;76(4):519-527. (Pubitemid 38580467)
44. Nascimento MM, Suliman ME, Silva M, et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: A placebo-controlled study. Perit Dial Int. 2010;30(3):336-342.
45. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorderVa double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64(6):468-475.